Mission Statement, Vision, & Core Values (2026) of Befar Group Co.,Ltd.

Founded in 2009, Befar Group Co., Ltd. has grown into a multifaceted healthcare company with a clear mission to deliver high-quality, internationally certified solutions (holding ISO 9001 and ISO 13485) and a vision to become a global leader in innovative medical devices, pharmaceuticals, and health products; last fiscal year the company reported revenue of $120 million, distributes more than 500 products across over 50 countries, and channels roughly 5% of revenue into R&D to fuel continuous innovation-anchored by core values of integrity, customer focus, sustainability, collaboration and excellence that drive its commitment to safety, efficacy and expanding global impact

Befar Group Co.,Ltd (601678.SS) Intro

• Core business lines: medical devices, health products, pharmaceuticals.
• Global footprint: distribution in 50+ countries and regions.
• Product breadth: over 500 SKU variants across therapeutic and device categories.
• Quality and compliance: ISO 9001 and ISO 13485 certified for quality management and medical device standards.
• R&D commitment: approximately 5% of annual revenue invested in research and development (~$6.0M on a $120M revenue base).

• Quality Assurance: sustained adherence to international medical device and pharmaceutical standards.
• Market Expansion: leveraging distribution partnerships to enter new regional markets.
• Innovation Pipeline: focused R&D programs funded at ~5% of revenue to develop next-generation devices and formulations.
• Operational Efficiency: continuous improvement programs to support an 8% CAGR and margin preservation.

Befar Group Co.,Ltd (601678.SS) - Overview

Befar Group Co.,Ltd centers its corporate identity around a mission to deliver high-quality healthcare solutions driven by continuous innovation, rigorous quality assurance, customer focus, and sustainable practices. The company's strategic priorities translate into measurable commitments across R&D, quality systems, market expansion, and environmental initiatives.

• Mission: Provide high-quality healthcare solutions through continuous innovation and adherence to international standards.
• Vision: Become a globally recognized medical technology and consumables provider that improves health outcomes worldwide.
• Core values: Innovation, Quality, Customer-focus, Sustainability, Compliance.

Key operational and financial indicators that underpin the mission and values:

How the mission translates into concrete actions and metrics:

• Innovation pipeline: sustained R&D spend and clinical collaborations to shorten time-to-market for new consumables and devices.
• Quality systems: maintenance of ISO/CE certifications and investment in GMP-compliant facilities to meet international safety and efficacy standards.
• Customer-centric product development: segment-specific solutions for hospitals, clinics, and distributors with targeted after-sales support and training.
• Sustainability initiatives: waste-reduction programs in manufacturing, energy-efficiency upgrades, and supplier environmental assessments to lower operational carbon intensity.
• Global health impact: expanding export channels and partnerships to deliver cost-effective products to emerging markets, improving access to essential medical supplies.

Representative operational KPIs that Befar monitors to ensure mission execution:

• R&D projects initiated per year: ≈ 30-50
• Product approval lead time reduction target: 10% year-over-year
• Customer satisfaction / service response SLA attainment: ≥ 90%
• Manufacturing yield improvement target: 3%-5% annual gain

For a closer look at investor-related signals and market interest in Befar Group Co.,Ltd, see: Exploring Befar Group Co.,Ltd Investor Profile: Who's Buying and Why?

Befar Group Co.,Ltd (601678.SS) - Mission Statement

• Become a leading global provider of innovative healthcare solutions, expanding presence in existing and new markets.
• Grow the distribution network to reach a broader customer base across Asia, Europe, the Americas, Africa and Oceania.
• Maintain and elevate product quality to meet the most stringent international standards (ISO, CE, CFDA/NMPA compliance and equivalent certifications).
• Forge long-term partnerships with hospitals, distributors, NGOs and public-health organizations to improve healthcare delivery.
• Lead in R&D to introduce technologies and products addressing emerging clinical needs (medical adhesives, wound care, infection control, and related disposables).
• Operate with sustainable and ethical business practices that contribute to global health advancement and carbon-responsible manufacturing.

• Patient-centricity - prioritize safety, efficacy and accessibility of products.
• Quality & Compliance - uphold rigorous manufacturing and regulatory standards.
• Innovation - invest in R&D and adopt new technologies for better clinical outcomes.
• Collaboration - seek partnerships across healthcare stakeholders for shared impact.
• Integrity & Responsibility - transparent governance, ethical supply chains and environmental stewardship.

• Scale global distribution: target +20% country coverage year-over-year until reaching 75+ countries within five years.
• Increase R&D intensity: sustain R&D at ≥8% of revenue to accelerate product pipeline (advanced wound care, infection prevention, consumables).
• Quality assurance: expand certified quality management systems across all manufacturing sites and achieve additional international approvals for core product families.
• Partnership development: sign strategic supply and clinical partnership agreements with 25+ leading hospitals and distributors in priority regions by 2026.
• Sustainability targets: reduce manufacturing CO2 intensity by 30% per unit product by 2030 and implement supplier audits for ethical sourcing.

• Targeted M&A and licensing to access new technologies and regional channels.
• Accelerated clinical studies and regulatory submissions in key markets (EU, US, ASEAN, MENA).
• Digitization of supply chain and quality systems to improve traceability and compliance.
• Training programs for partners and clinicians to drive adoption and proper use of products.

Befar Group Co.,Ltd (601678.SS) - Vision Statement

• Integrity: All operations adhere to transparent governance, regulatory compliance, and ethical conduct in procurement, production, and sales.
• Innovation: Continuous investment in R&D to create differentiated specialty chemical formulations and advanced materials.
• Customer focus: Product roadmaps and service models are aligned to measurable customer outcomes and retention metrics.
• Sustainability: Commitments to emissions reduction, energy efficiency, and circular material use across manufacturing sites.
• Collaboration: Cross-functional and industry partnerships accelerate commercialization and scale.
• Excellence: Operational discipline and quality systems drive industry-leading product performance and safety records.

• Integrity - strengthened compliance: annual third-party audits across 100% of manufacturing sites and a 0% tolerance whistleblower escalation protocol.
• Innovation - pipeline metrics: >45 active product projects, 12 patents granted in the last 12 months, and R&D teams located across three technology centers.
• Customer focus - service KPIs: >92% on-time delivery, 88% customer satisfaction in industrial accounts, and key-account churn below 4%.
• Sustainability - targets: 25% renewable-energy usage by 2026, 15% reduction in water intensity vs. 2021 baseline, and ongoing waste-to-recycle programs.
• Collaboration - partnerships: strategic supply agreements with 8 upstream suppliers and technology collaborations with 4 universities/research institutes.
• Excellence - quality & safety: ISO 9001 and ISO 45001 certified sites; LTIFR (lost-time injury frequency rate) at 0.12 per 200,000 hours.

• Dividend policy: progressive payout with payout ratio around 25-30% of net profit.
• Disclosure: quarterly operational updates, sustainability report aligned to TCFD elements and annual ESG metrics.
• Capital allocation: prioritize high-ROI capacity expansion, product premiumization, and digitalization of supply chain.